Company intelligence / Profile preview
Envisia Therapeutics
Durham, North Carolina, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Phase II studies for ENV515 (travoprost) showed promising results with the high dose ENV515-3 demonstrating a 28% drop in pressure and 6.7 mmHg drop in IOP, numerically equivalent to Travatan Z. The low-dose (ENV515-1) showed about a 20% drop in pressure. The company was working toward optimization for anticipated Phase III studies.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- Small moleculesparticle-based therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Liquidia Technologies
Beyond the preview
Go deeper on Envisia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Envisia Therapeutics.